These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7580589)

  • 21. Pharmaceutical care for elderly patients shared between community pharmacists and general practitioners: a randomised evaluation. RESPECT (Randomised Evaluation of Shared Prescribing for Elderly people in the Community over Time) [ISRCTN16932128].
    Wong I; Campion P; Coulton S; Cross B; Edmondson H; Farrin A; Hill G; Hilton A; Philips Z; Richmond S; Russell I
    BMC Health Serv Res; 2004 Jun; 4(1):11. PubMed ID: 15182379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Knowledge of and attitudes about adverse drug reaction reporting among Rhode Island pharmacists.
    Generali JA; Danish MA; Rosenbaum SE
    Ann Pharmacother; 1995 Apr; 29(4):365-9. PubMed ID: 7633012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perceived barriers to pharmacist engagement in adverse drug event prevention activities in Ghana using semi-structured interview.
    Acheampong F; Anto BP
    BMC Health Serv Res; 2015 Sep; 15():361. PubMed ID: 26345278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient reporting improves pharmacovigilance.
    Prescrire Int; 2008 Dec; 17(98):241-2. PubMed ID: 19422153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nutravigilance: principles and practices to enhance adverse event reporting in the dietary supplement and natural products industry.
    Schmitz SM; Lopez HL; MacKay D
    Int J Food Sci Nutr; 2014 Mar; 65(2):129-34. PubMed ID: 24112316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nurses must report adverse drug reactions.
    Griffith R
    Br J Nurs; 2013 Apr 25-May 8; 22(8):484-5. PubMed ID: 23905231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring drug safety--the power or the yellow form.
    Mehta U; Gunston G; O'Connor N
    S Afr Med J; 1998 Aug; 88(8):924. PubMed ID: 9754195
    [No Abstract]   [Full Text] [Related]  

  • 28. Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland.
    O'Callaghan J; Griffin BT; Morris JM; Bermingham M
    BioDrugs; 2018 Jun; 32(3):267-280. PubMed ID: 29721705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic and safety benefits of pharmaceutical interventions by community and hospital pharmacists in Japan.
    Tasaka Y; Yasunaga D; Tanaka M; Tanaka A; Asakawa T; Horio I; Miyauchi Y; Araki H
    Int J Clin Pharm; 2016 Apr; 38(2):321-9. PubMed ID: 26744362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ASHP guidelines on adverse drug reaction monitoring and reporting. American Society of Hospital Pharmacy.
    Am J Health Syst Pharm; 1995 Feb; 52(4):417-9. PubMed ID: 7757870
    [No Abstract]   [Full Text] [Related]  

  • 31. Improving medicines for children in Canada. Findings of the expert panel on therapeutic products for infants, children and youth.
    Koren G
    J Popul Ther Clin Pharmacol; 2014; 21(3):e518-9. PubMed ID: 25527797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health professionals: how do they assess new medicines?
    Cheng R; Cook K; Dowman S; Lawn R; Leary J; Quinn T; Schroder K; Smith N; Tordoff J
    Pharm World Sci; 2005 Jun; 27(3):236-42. PubMed ID: 16096894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of the doctor in drug safety.
    Ti TY
    Ann Acad Med Singap; 1993 Jan; 22(1):54-6. PubMed ID: 8503639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The Medical Products Agency is responsible for the control of medical technological products: we need more active medical professionals reporting shortages].
    Philipson L
    Lakartidningen; 2008 Mar 5-11; 105(10):746-7. PubMed ID: 18422241
    [No Abstract]   [Full Text] [Related]  

  • 36. An observational study to compare the contents and quality of information furnished in CDSCO ADR reporting form, yellow card, medwatch and blue form by the healthcare professionals.
    Rehan HS; Chopra D; Holani SN; Mishra R
    Int J Risk Saf Med; 2014; 26(1):1-8. PubMed ID: 24796346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two UK Government proposals bearing on drug safety.
    Griffin JP
    Adverse Drug React Toxicol Rev; 1997 Mar; 16(1):1-7. PubMed ID: 9192053
    [No Abstract]   [Full Text] [Related]  

  • 38. Medication risk mitigation matrix: A pharmaceutical care opportunity for precision medication.
    Knowlton CH
    J Am Pharm Assoc (2003); 2015; 55(4):354-8. PubMed ID: 25820799
    [No Abstract]   [Full Text] [Related]  

  • 39. Patient safety problem identification and solution sharing among rural community pharmacists.
    Galt KA; Fuji KT; Faber J
    J Am Pharm Assoc (2003); 2013; 53(6):584-94. PubMed ID: 24092473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse Effects of Common Drugs: General Concepts.
    Karpa KD; Lewis PR; Felix TM
    FP Essent; 2015 Sep; 436():11-6. PubMed ID: 26375993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.